R
Robert Tibshirani
Researcher at Stanford University
Publications - 620
Citations - 359457
Robert Tibshirani is an academic researcher from Stanford University. The author has contributed to research in topics: Lasso (statistics) & Gene expression profiling. The author has an hindex of 147, co-authored 593 publications receiving 326580 citations. Previous affiliations of Robert Tibshirani include University of Toronto & University of California.
Papers
More filters
Journal ArticleDOI
Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation
Holbrook E Kohrt,Lu Tian,Li Li,Ash A. Alizadeh,Sue Hsieh,Robert Tibshirani,Samuel Strober,Minnie M. Sarwal,Robert Lowsky +8 more
TL;DR: The dominant gene signature in patients with chronic GVHD represented compensatory responses that control inflammation and included the interleukin-1 decoy receptor, IL-1 receptor type II, and genes that were profibrotic and associated with the IL-4,IL-6 and IL-10 signaling pathways.
Posted Content
Principal component-guided sparse regression
TL;DR: A new method for supervised learning that combines the lasso (ℓ1) penalty with a quadratic penalty that shrinks the coefficient vector toward the feature matrix's leading principal components (PCs).
Posted ContentDOI
Polygenic risk modeling with latent trait-related genetic components
Matthew Aguirre,Yosuke Tanigawa,Guhan Venkataraman,Robert Tibshirani,Trevor Hastie,Manuel A. Rivas +5 more
TL;DR: A latent factor model of genetic risk based on components from Decomposition of Genetic Associations (DeGAs), which is called the DeGAs polygenic risk score (dPRS) is introduced and finds that dPRS performs comparably to standard PRS while offering greater interpretability.
Journal ArticleDOI
Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma
Holbrook E Kohrt,Jaqueline Chu,Joshua Brody,Debra K. Czerwinski,Cariad Chester,Mohith Sadaram,Ranjana H. Advani,Youn H. Kim,Richard T. Hoppe,Susan J. Knox,Irene Wapnir,Robert Tibshirani,Ronald Levy +12 more
TL;DR: In response to in situ vaccination, all patients made tumor-specific immune responses within 2 to 4 weeks post-vaccination with the most informative markers being the activation marker CD278 (ICOS) for CD4 T cell response among the CD45RO+ memory subset, and perforin and granzyme B for CD8 T cell responses.